conventionally fractionated full dose re-irradiation
Radiationre-irradiation [60-70 Gy (RBE) in 2 Gy (RBE) fractions
NCT Number: NCT03217188
The purpose of this study is to evaluate the tumor control and the side effects of using proton therapy for head and neck cancer that has come back.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Baptist Alliance MCI, Miami, Florida, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
re-irradiation [60-70 Gy (RBE) in 2 Gy (RBE) fractions
course or a hypofractionated palliative re-irradiation "Quad Shot" course (3.7 Gy (RBE) twice daily x 2 days, followed by a 4 week break [+/- 2 weeks], repeated up to 4 cycles).
Time frame: 12 months
Locoregional recurrence includes events of local and/or regional recurrence, or death due to any cause. Patients who are lost to follow-up without any event may be removed from the protocol at the discretion of the principal investigator.
Memorial Sloan Kettering Cancer Center
Other
A Phase II Study of Proton Re-Irradiation for Recurrent Head and Neck Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05570851
Alcohol Drinking, Alcohol Use, Unspecified
Manhasset, New York, United States
View Trial DetailsNCT04208490
Head and Neck Cancer, Head and Neck Neoplasms
Kingman, Arizona, United States
View Trial DetailsNCT03117946
Head and Neck Cancer, Head and Neck Neoplasms
Besançon, France
View Trial DetailsNCT00076310
Carcinoma, Carcinoma, Squamous Cell
Houston, Texas, United States
View Trial Details